Cargando…

DeepNEU: cellular reprogramming comes of age – a machine learning platform with application to rare diseases research

BACKGROUND: Conversion of human somatic cells into induced pluripotent stem cells (iPSCs) is often an inefficient, time consuming and expensive process. Also, the tendency of iPSCs to revert to their original somatic cell type over time continues to be problematic. A computational model of iPSCs ide...

Descripción completa

Detalles Bibliográficos
Autor principal: Danter, Wayne R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327463/
https://www.ncbi.nlm.nih.gov/pubmed/30630505
http://dx.doi.org/10.1186/s13023-018-0983-3
_version_ 1783386471421444096
author Danter, Wayne R.
author_facet Danter, Wayne R.
author_sort Danter, Wayne R.
collection PubMed
description BACKGROUND: Conversion of human somatic cells into induced pluripotent stem cells (iPSCs) is often an inefficient, time consuming and expensive process. Also, the tendency of iPSCs to revert to their original somatic cell type over time continues to be problematic. A computational model of iPSCs identifying genes/molecules necessary for iPSC generation and maintenance could represent a crucial step forward for improved stem cell research. The combination of substantial genetic relationship data, advanced computing hardware and powerful nonlinear modeling software could make the possibility of artificially-induced pluripotent stem cells (aiPSC) a reality. We have developed an unsupervised deep machine learning technology, called DeepNEU that is based on a fully-connected recurrent neural network architecture with one network processing layer for each input. DeepNEU was used to simulate aiPSC systems using a defined set of reprogramming transcription factors. Genes/proteins that were reported to be essential in human pluripotent stem cells (hPSC) were used for system modelling. RESULTS: The Mean Squared Error (MSE) function was used to assess system learning. System convergence was defined at MSE < 0.001. The markers of human iPSC pluripotency (N = 15) were all upregulated in the aiPSC final model. These upregulated/expressed genes in the aiPSC system were entirely consistent with results obtained for iPSCs. CONCLUSION: This research introduces and validates the potential use of aiPSCs as computer models of human pluripotent stem cell systems. Disease-specific aiPSCs have the potential to improve disease modeling, prototyping of wet lab experiments, and prediction of genes relevant and necessary for aiPSC production and maintenance for both common and rare diseases in a cost-effective manner.
format Online
Article
Text
id pubmed-6327463
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63274632019-01-15 DeepNEU: cellular reprogramming comes of age – a machine learning platform with application to rare diseases research Danter, Wayne R. Orphanet J Rare Dis Research BACKGROUND: Conversion of human somatic cells into induced pluripotent stem cells (iPSCs) is often an inefficient, time consuming and expensive process. Also, the tendency of iPSCs to revert to their original somatic cell type over time continues to be problematic. A computational model of iPSCs identifying genes/molecules necessary for iPSC generation and maintenance could represent a crucial step forward for improved stem cell research. The combination of substantial genetic relationship data, advanced computing hardware and powerful nonlinear modeling software could make the possibility of artificially-induced pluripotent stem cells (aiPSC) a reality. We have developed an unsupervised deep machine learning technology, called DeepNEU that is based on a fully-connected recurrent neural network architecture with one network processing layer for each input. DeepNEU was used to simulate aiPSC systems using a defined set of reprogramming transcription factors. Genes/proteins that were reported to be essential in human pluripotent stem cells (hPSC) were used for system modelling. RESULTS: The Mean Squared Error (MSE) function was used to assess system learning. System convergence was defined at MSE < 0.001. The markers of human iPSC pluripotency (N = 15) were all upregulated in the aiPSC final model. These upregulated/expressed genes in the aiPSC system were entirely consistent with results obtained for iPSCs. CONCLUSION: This research introduces and validates the potential use of aiPSCs as computer models of human pluripotent stem cell systems. Disease-specific aiPSCs have the potential to improve disease modeling, prototyping of wet lab experiments, and prediction of genes relevant and necessary for aiPSC production and maintenance for both common and rare diseases in a cost-effective manner. BioMed Central 2019-01-10 /pmc/articles/PMC6327463/ /pubmed/30630505 http://dx.doi.org/10.1186/s13023-018-0983-3 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Danter, Wayne R.
DeepNEU: cellular reprogramming comes of age – a machine learning platform with application to rare diseases research
title DeepNEU: cellular reprogramming comes of age – a machine learning platform with application to rare diseases research
title_full DeepNEU: cellular reprogramming comes of age – a machine learning platform with application to rare diseases research
title_fullStr DeepNEU: cellular reprogramming comes of age – a machine learning platform with application to rare diseases research
title_full_unstemmed DeepNEU: cellular reprogramming comes of age – a machine learning platform with application to rare diseases research
title_short DeepNEU: cellular reprogramming comes of age – a machine learning platform with application to rare diseases research
title_sort deepneu: cellular reprogramming comes of age – a machine learning platform with application to rare diseases research
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327463/
https://www.ncbi.nlm.nih.gov/pubmed/30630505
http://dx.doi.org/10.1186/s13023-018-0983-3
work_keys_str_mv AT danterwayner deepneucellularreprogrammingcomesofageamachinelearningplatformwithapplicationtorarediseasesresearch